Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

Ítems similars

• Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism
  per: Plaza-Menacho, Iván, et al.
  Publicat: (2011)
• Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement
  per: Henderson, Ying C., et al.
  Publicat: (2008)
• Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line
  per: Tartari, Carmen J, et al.
  Publicat: (2011)
• ESCRTing proteasomes to the lysosome
  per: Segev, Nava
  Publicat: (2020)
• GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors
  per: Morandi, Andrea, et al.
  Publicat: (2013)